Viral Infections
RSSArticles
-
COVID-19 Vaccine and the Menstrual Cycle
In a retrospective cohort analysis of prospectively tracked menstrual cycle data from the smartphone application “Natural Cycles,” the COVID-19 vaccine was associated with a less than one day change in menstrual cycle length and no change in menses length.
-
Infectious Disease Alert Updates
Recovering from Critical COVID; Oral and Anal Transmission of Syphilis
-
A Case of Monkeypox in a Returned Traveler
The arrival of a traveler from Nigeria to the United States with monkeypox infection, which was quickly recognized, led to a massive public health response investigating exposed individuals, but no secondary cases were detected.
-
Maribavir (Livtencity)
The FDA approved maribavir as the first drug to treat adult and pediatric patients with post-transplant cytomegalovirus infections that do not respond to currently available antiviral treatment.
-
Persistent Inflammation and Post-COVID Syndrome
Ongoing inflammation may contribute to long COVID.
-
Bloodstream Infections During COVID-19
Severity of illness, prolonged hospital stays, use of mechanical ventilation, and use of immune-modulating agents in patients with COVID-19 may have contributed to observed increases in hospital-acquired blood stream infections and attendant mortality.
-
Why Some Children Develop Severe COVID-19 Disease
Severe outcomes included cardiovascular complications, neurologic complications, respiratory problems, and infectious-related issues. Those with pre-existing chronic disease, older age, and longer symptom duration put them at serious risk for severe outcomes.
-
ACC Publishes Guidance on Managing Cardiovascular Ailments Post-COVID Infection
Expert panel created document to help clinicians manage patients with myocarditis and other long COVID problems associated with SARS-CoV-2.
-
Rats in Washington, DC? The Seoul of the Issue
The Centers for Disease Control and Prevention has reported cases of the Seoul hantavirus in Washington, DC.
-
Bebtelovimab Injection
The FDA has issued an emergency use authorization for a monoclonal antibody that demonstrated efficacy against the omicron variant of COVID-19.